Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things, hear about whether safety concerns may affect JAK inhibitors, Takeda’s strategic R&D plans, Cigna’s psoriasis insurance program, Phase III readouts to look for, and an overview of the global pharma R&D pipeline.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 April 2021, including: safety concerns for JAK inhibitors; Takeda’s R&D plans; Cigna’s psoriasis insurance program; upcoming Phase III readouts to look out for; and an overview of the global R&D pipeline.

These and all other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider. 

Stories mentioned in this episode:

(Also see "What Will JAK Inhibitor Safety Jitters Mean For Drug Sales?" - Scrip, 7 Apr, 2021.)

(Also see "Takeda Highlights Rare Neurological Disorder Programs In Wave 1" - Scrip, 6 Apr, 2021.)

(Also see "Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx" - Scrip, 6 Apr, 2021.)

(Also see "Five Phase III Data Readouts To Look Out For In Q2" - Scrip, 7 Apr, 2021.)

(Also see "COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth" - Scrip, 5 Apr, 2021.)

 

Related Content

Topics

UsernamePublicRestriction

Register

SC144148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel